In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae

L Tselepis, G W Langley, A F Aboklaish, E Widlake, D E Jackson, T R Walsha C J Schofield, J Brem, J M Tyrrell

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

OBJECTIVES: In vitro evaluation of the potential clinical efficacy of the novel β-lactam/β-lactamase-inhibitor combinations including imipenem-relebactam (IPM-REL) and cefepime-AAI101 (enmetazobactam) (FEP-AAI) against contemporary multidrug-resistant Enterobacteriaceae.

METHODS: Agar-based MIC screening against MDR-Enterobacteriaceae (n=264) was used to evaluate the in vitro efficacy of IPM-REL and FEP-AAI, to compare the results with established combinations, and to investigate alternative β-lactam partners for REL and AAI. The inhibition activities of REL, AAI and the comparators avibactam (AVI) and tazobactam, against isolated recombinant β-lactamases covering representatives from all four Ambler classes of β-lactamases were tested using a fluorescence-based assay.

RESULTS: Using recombinant proteins, all four inhibitors were highly active against the tested class A serine β-lactamases (SBLs); REL and AVI showed moderate activity against the Class C AmpC from P. aeruginosa and the Class D OXA-10/-48 SBLs, but outperformed tazobactam and AAI. All tested inhibitors lacked activity against Class B MBLs. In the presence of REL, IPM, but not AAI susceptibility increased against KPC-positive and OXA-48-positive isolates. Both aztreonam-AVI and ceftolozane-tazobactam were more efficacious than IPM-REL. In all the tested combinations, AAI was a more effective inhibitor of class A β-lactamases (ESBLs) than the established inhibitors.

CONCLUSIONS: The results lead to the proposal of alternative combination therapies involving REL and AAI to potentiate the use of β-lactams against clinical Gram-negative isolates expressing a variety of β-lactamases. These results highlight the potential of novel combinations for combating strains not covered by existing therapies.

Original languageEnglish
Pages (from-to)105925
JournalInternational Journal of Antimicrobial Agents
Early online date18 Feb 2020
DOIs
Publication statusE-pub ahead of print - 18 Feb 2020

Bibliographical note

Copyright © 2020. Published by Elsevier B.V.

Fingerprint Dive into the research topics of 'In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this